371 related articles for article (PubMed ID: 35403540)
1. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
3. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
Pollock RF; Biggar P
Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
Auerbach M; Achebe MM; Thomsen LL; Derman RJ
Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
[TBL] [Abstract][Full Text] [Related]
5. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
6. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
[TBL] [Abstract][Full Text] [Related]
7. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis].
Ding SX; Zhao YH; Wang T; Guan J; Xing LM; Liu H; Wang GJ; Wang XM; Wu YH; Qu W; Song J; Wang HQ; Li LJ; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):178-183. PubMed ID: 38604795
[No Abstract] [Full Text] [Related]
10. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
Yun L; YuMei Z; Bn V; Tang Q; Feng C
Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
[TBL] [Abstract][Full Text] [Related]
12. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
[TBL] [Abstract][Full Text] [Related]
13. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
Loughnane F; Muduma G; Pollock RF
Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
Fukumoto S; Murata T; Osuga Y; Pollock RF
Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
[TBL] [Abstract][Full Text] [Related]
15. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
16. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]